GOTHENBURG, Sweden, April 26, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the resolutions adopted at the Annual General Meeting held in Gothenburg.
The following resolutions were adopted at the Annual General Meeting (the "AGM") of Immunicum AB (publ), reg. no 556629-1786. For more detailed information regarding the contents of the resolutions, please refer to the notice of the AGM and the complete proposals, which have previously been published and are available on the Company's website by using the following links:
English: http://immunicum.se/investors/corporate-governance/general-meeting/
Swedish: http://immunicum.se/investerare-se/bolagsstyrning/bolagsstamma/
Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liability
The AGM adopted the Company's balance sheet and income statement. The AGM resolved that no dividends shall be paid for the financial year 1 July 2016 - 31 December 2016. The AGM further resolved that the Company's accumulated losses shall be appropriated so that SEK 151,447,096 is settled against the share premium reserve and that the remaining SEK 101,088,126 is carried forward. The AGM also discharged the board members and the managing director from liability for the financial year 1 July 2016 - 31 December 2016.
Election of board members and auditor
The AGM resolved that the board of directors shall consist of seven board members.
The AGM re-elected the current board members Agneta Edberg, Martin Lindström, Magnus Nilsson, Magnus Persson, Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm as board members. Agneta Edberg was re-elected as chairman of the board of directors.
The AGM resolved to reappoint the registered public accounting firm KPMG AB as auditor for the period until the next annual general meeting. KPMG AB has announced that the authorized public accountant Jan Malm will be the auditor in charge.
Remuneration to the board of directors and auditor
The AGM decided that remuneration to the board of directors shall be paid with SEK 1,185,000, to be distributed as follows: board members are remunerated with SEK 125,000 each, in addition the chairman of the board of directors is remunerated with SEK 170,000. A board member who is a member of the scientific committee is remunerated with SEK 25,000, in addition a board member who is chairman of the scientific committee is remunerated with SEK 25,000. A board member who is a member of the audit committee is remunerated with SEK 15,000, in addition a board member who is chairman of the audit committee is remunerated with SEK 20,000. No other remuneration for committee work shall be paid. The AGM further resolved that, in addition to board fees, the board of directors as a whole may be remunerated with a maximum of SEK 100,000 for work outside the scope of the ordinary work of the board of directors and that board member may be allowed by the Company to invoice the remuneration through a Company provided that it is cost neutral for the Company.
The AGM decided that remuneration to the auditor shall be paid according to approved invoices.
Authorization for the board of directors to decide on new share issues and issues of warrants and/or convertibles
The AGM resolved to authorize the board of directors to resolve, for the period until the end of the next annual general meeting, at one or more occasions and with or without deviation from the shareholders' preferential rights, to issue a maximum of 2,595,000 new shares and warrants or convertible debentures giving a right to subscribe for a maximum of 2,595,000 shares. Payment shall be made in cash. If fully exercised, the authorization corresponds to approximately 10 percent of the current share capital and votes in the Company.
Resolution regarding principles for the appointment of the nomination committee
The AGM resolved to adopt principles for the appointment of the nomination committee in accordance with the nomination committee's proposal.
Resolution regarding guidelines for remuneration to senior executives
The AGM resolved to adopt guidelines for remuneration to senior executives in accordance with the board of directors' proposal.
About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage Company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Dr. Stephanie May
Telephone: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
The information in this press release is disclosed pursuant to the rules for companies listed on Nasdaq First North Premier. The information was released for public disclosure through the agency of the Company's contact person on April 26, 2017 at 13:30 CET.